Controlled Trial of Dipyridamole in Cerebral Vascular Disease

Acheson, Joan; Danta, G; Hutchinson, E. C.

doi:10.1136/bmj.1.5644.614

Cited by 178 publications

(46 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, the identified trials probably represent the totality of trial evidence relating to dipyridamole in patients with cerebrovascular disease, and it is unlikely that the results are biased by a failure to include relevant studies. Bias may also result if data from some identified studies are unavailable, as occurred here with 2 studies, 13,17 although the missing data comprised Ͻ2% of the total data set. Including tabular data from these trials did not alter the results.…”

Section: Leonardi-bee Et Al Dipyridamole For Preventing Recurrent Strokementioning

confidence: 96%

Section: Trialsmentioning

confidence: 99%

“…3,[13][14][15][16][17][18] Individual patient data from 2 small studies (nϭ169 and nϭ50; amounting to 1.9% of total data) were unavailable. 13,17 Data from a nonrandomized controlled clinical study were only included in sensitivity analyses (Table 1). 19 Two ongoing studies were excluded: ESPRIT (AD/A) 20 and PRoFESS, 21 the latter compared combined aspirin and dipyridamole with clopidogrel alone.…”

Section: Trialsmentioning

confidence: 99%

See 2 more Smart Citations

Dipyridamole for Preventing Recurrent Ischemic Stroke and Other Vascular Events

Leonardi‐Bee

Bath

Bousser

et al. 2005

Stroke

116

View full text Add to dashboard Cite

on behalf of the Dipyridamole in Stroke Collaboration (DISC)Background and Purpose-Results from randomized controlled trials of dipyridamole, given with or without aspirin, for secondary prevention after ischemic stroke or transient ischemic attack (TIA) have given conflicting results. We performed a meta-analysis using individual patient data from relevant randomized controlled trials. Methods-Randomized controlled trials involving dipyridamole in patients with previous ischemic stroke or TIA were sought from searches of the Cochrane Library, other electronic databases, references lists, earlier reviews, and contact with the manufacturer of dipyridamole. Individual patient data were merged from 5 of 7 relevant trials involving 11 459 patients. Results were adjusted for age, gender, qualifying event, and history of previous hypertension. Results-Recurrent

show abstract

Section: Leonardi-bee Et Al Dipyridamole For Preventing Recurrent Strokementioning

confidence: 96%

Section: Trialsmentioning

confidence: 99%

Section: Trialsmentioning

confidence: 99%

See 1 more Smart Citation

Dipyridamole for Preventing Recurrent Ischemic Stroke and Other Vascular Events

Leonardi‐Bee

Bath

Bousser

et al. 2005

Stroke

116

View full text Add to dashboard Cite

show abstract

“…The first was dipyridamole. 8 In a small and inadequately designed trial it did not prevent stroke. The next 2, sulfinpyrazone and aspirin, were tested in a factorial design trial (the Canadian aspirin trial as it became known).…”

Section: April 2014mentioning

confidence: 99%

Four Decades of Stroke Prevention Trials

Barnett

2014

Stroke

View full text Add to dashboard Cite

“…Acheson et al 42 reported a controlled double-blind study of the effect of dipyridamole in 169 patients with known cerebrovascular disease. Each patient had partially or completely recovered from a clinical episode of focal cerebral ischemia.…”

Section: Clotting Characteristics -Platelet Antiagglutinating Agentsmentioning

confidence: 99%

Treatment of transient ischemic attacks.

Millikan¹,

McDowell²

1978

Stroke

View full text Add to dashboard Cite

SUMMARY Transient ischemic attacks are the most important warning symptoms of impending stroke. They occur in up to one-half of all patients who develop stroke but, unfortunately, less than half of the patients who have them seek help from their physicians before stroke occurs. Physicians should regularly question patients about the possibility of such symptoms and patients with them should seek prompt help. When transient ischemic attack is diagnosed, patients should be evaluated for elevated blood pressure, hyperlipidemia, cardiac dysrhythmia, cardiac disease, anemia, polycythemia and thrombocytosis. When these conditions are found they should be treated. Patients with carotid system TIAs should be evaluated clinically and radiologically for evidence of vascular disease. The neck should be auscultated for bruit and absent pulses and the peripheral vessels palpated. Patients with carotid system TIAs should have angiography of all 4 cerebral vessels and the angiogram should be evaluated for the presence and number of arterial stenoses and the presence of ulcerated plaques. When patients with carotid system TIAs are found to have localized extracranial atherosclerotic obstruction or ulcerated plaques in a vessel appropriate to the side of their symptoms of cerebral ischemia, they should be considered for prompt surgical correction of the lesion. For patients with carotid system TIAs, who have multiple sites of extracranial vascular disease, medical treatment is advisable with either anticoagulants or platelet antiaggregating agents. In view of the recently reported favorable results using aspirin in the prevention of TIA and stroke, this agent may be preferable to anticoagulants in instances where hypertension, patient compliance and laboratory facilities are a problem.

show abstract

Controlled Trial of Dipyridamole in Cerebral Vascular Disease

Cited by 178 publications

References 12 publications

Dipyridamole for Preventing Recurrent Ischemic Stroke and Other Vascular Events

Dipyridamole for Preventing Recurrent Ischemic Stroke and Other Vascular Events

Four Decades of Stroke Prevention Trials

Treatment of transient ischemic attacks.

Contact Info

Product

Resources

About